Protocol and apparatus for determining heparin-induced thrombocytopenia

A technology for thrombocytopenia and platelet activation, which is used in biochemical equipment and methods, microbial determination/inspection, material inspection products, etc., and can solve the problems of impossible detection of anticoagulant degree, high cost, and uncontrollable bleeding.

Active Publication Date: 2006-10-25
希缪司构普公司
View PDF6 Cites 27 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, other substances are more expensive, and it is difficult or impossible to measure the degree of anticoagulation to prescribe the correct drug to the patient to prevent an ischemic event
These anticoagulants also lack the substances necessary to reverse their anticoagulant effect, which can lead to uncontrolled bleeding after surgery

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protocol and apparatus for determining heparin-induced thrombocytopenia
  • Protocol and apparatus for determining heparin-induced thrombocytopenia
  • Protocol and apparatus for determining heparin-induced thrombocytopenia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1: Determination of HiT II using platelet-rich plasma from normal donors mixed with citrated plasma from HiT II patients

[0042] Whole blood from a normal blood donor was drawn and transferred to a plastic centrifuge tube, which contained 5 μl˜15 μl of PPACK per 1 ml of blood. Normal blood donors should have a platelet count greater than 150,000 / μl and are not taking NSAIDS (non-steroidal anti-inflammatory drugs) or other platelet inhibitors. For a typical assay, 12 ml of blood is drawn and added to a tube containing about 180 μl of PPACK, which is capped and mixed by inversion several times, eg 3 times. The samples were centrifuged at 100 g for 20 minutes (800 RPM (revolutions per minute) for a standard IEC benchtop centrifuge) to separate platelet rich plasma (PRP) from other blood cells. This procedure will yield enough PRP for 3 to 4 assay mixtures, and excess PRP can be stored at -35°C to -70°C until assayed.

[0043] Prepare the PRP-patient plasma mixtu...

Embodiment 2

[0050] Example 2: Determination of HiT II using patient whole blood

[0051] A 3 ml sample of whole blood from a HiT II suspect patient was drawn into a plastic tube containing approximately 5 μl of 5 mg / ml PPACK per 1 ml of blood. The patient's platelet count should be greater than 50,000 / μl. Additionally, patients should not take GPIIb / IIIa inhibitor drugs such as Reopro(R), Integrilin(R), and Aggrestat, or other drugs that mask platelet activation by the HiT II antibody complex.

[0052] For a typical assay, 6 ml of patient blood is drawn into a plastic tube containing 30 μl of PPACK and mixed. This provides enough blood sample for assay and enough remaining blood sample for separation of plasma to be used for confirmatory testing with normal donor blood as described in Example 1 above, especially if the patient's platelet count is less than 50,000 / μl.

[0053] Prepare four sample containers for testing. Add 5 µl of saline to the first sample container. Add 5 μl of 1 U / ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A hemostasis analyzer, such as the Thrombelastograph (TEG) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit determination of heparin-induced thrombocytopenia II complex (HiT II).

Description

[0001] Cross-references to related applications [0002] This application is related to the following commonly owned U.S. patents and patent applications: U.S. Patent Application Serial No. 09 / 591,371, filed June 9, 2000, entitled "Methods and Apparatus for Monitoring Antiplatelet Agents"; U.S. Patent Application Serial No. 10 / 384,345, filed March 2, 2003, entitled "Protocol for Monitoring Platelet Inhibition"; U.S. Patent Application Serial No. 10 / 409,479, "Method and Apparatus for Hemostasis Related to Man-made Watch Devices"; and U.S. Patent Application Serial No. 6,225,236, entitled "Method and Apparatus for Measuring Hemostasis," The disclosures of the aforementioned US patents and patent applications are expressly incorporated herein by reference. technical field [0003] The present invention relates to protocols and devices for determining heparin-induced thrombocytopenia (HiT). Background technique [0004] Blood is the body's circulating tissue that carries oxyge...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/86C12Q1/56
CPCC12Q1/56
Inventor 伊莱·科恩罗斯林·科恩罗杰·C·卡罗尔
Owner 希缪司构普公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products